In a groundbreaking study that promises to redefine our understanding of prostate cancer and androgen receptor (AR) biology, researchers have deployed a state-of-the-art prime editing technique to generate and functionally characterize nearly every possible single amino acid variant of the AR ligand-binding domain. This deep mutational scanning approach, unprecedented in scale and resolution, has forged a comprehensive atlas of AR variants that not only illuminates the molecular underpinnings of drug resistance in prostate cancer but also enhances the clinical toolkit for diagnosing androgen insensitivity syndrome (AIS).
Prostate cancer remains the most prevalent malignancy in men worldwide and a leading cause of cancer-related death. Central to its pathogenesis and progression is the androgen receptor, a steroid hormone receptor that mediates the effects of androgens such as testosterone. The receptor’s ligand-binding domain (LBD) plays a pivotal role by binding hormones and transducing signals that drive tumor growth and survival. Consequently, therapeutic strategies often target AR signaling either through antagonists like enzalutamide or through novel degraders such as bavdegalutamide. However, the efficacy of these treatments is frequently undermined by the emergence of AR variants that resist inhibition, posing a formidable clinical challenge.
The research team employed an advanced prime editing platform, a CRISPR-derived genome editing technique renowned for its precision and versatility, to systematically create and assay 2,765 AR variants. Remarkably, this collection encompasses 99.95% of all single amino acid variants encoded by single nucleotide changes within the AR LBD, an exhaustive coverage that is unparalleled in the study of nuclear receptors. By rigorously evaluating the functionality of each variant, the scientists identified 755 previously unknown AR mutations that abrogate receptor function, thereby providing new insights into the genetic causes of androgen insensitivity syndrome—a spectrum of developmental disorders arising from impaired AR activity.
Beyond cataloging non-functional variants, the study revealed hitherto unrecognized mutations conferring resistance to key anti-cancer agents. Specifically, 225 AR variants were found to confer resistance to enzalutamide, a front-line AR signaling inhibitor, while 40 variants exhibited resistance to bavdegalutamide, an experimental AR degrader designed to dismantle the receptor protein itself. These findings ripple across the landscape of precision oncology, highlighting the necessity of comprehensive mutation profiling in guiding therapeutic decisions and in anticipating treatment failure.
Technically, the use of prime editing enabled the introduction of precise, single-nucleotide substitutions without the off-target complexities associated with earlier genome editing methods. This precision allowed the authors not only to saturate the mutational space of the AR LBD but also to dissect the structural and functional consequences of individual amino acid changes within a cellular context. By integrating high-throughput screening with sophisticated computational modeling, the study dissected the complex genotype-phenotype relationships that dictate AR’s responsiveness to androgens and to pharmacological antagonists.
The implications of this work extend far beyond prostate cancer. The androgen receptor is a critical regulator of male sexual development, and germline mutations that impair its function underlie AIS, a condition marked by a spectrum of phenotypic outcomes from mild undervirilization to complete feminization in genetic males. Prior to this study, many AR variants detected clinically were categorized as variants of uncertain significance, limiting their utility in diagnosis and genetic counseling. The comprehensive functional map delivered by this research promises to revolutionize clinical decision-making by enabling precise prognostication and by identifying pathogenic mutations with unprecedented confidence.
Moreover, the delineation of mutation-driven drug resistance mechanisms informs the future design of second-generation AR inhibitors and degraders engineered to overcome resistance. The identification of 225 enzalutamide-resistant variants serves as a valuable resource for drug developers, potentially guiding the synthesis of compounds that retain efficacy in the context of diverse AR mutations. Simultaneously, the discovery of mutations resistant to bavdegalutamide sheds light on the vulnerabilities and adaptability of targeted protein degradation strategies, which represent a cutting-edge avenue in cancer therapeutics.
Importantly, the comprehensive mutation dataset also enabled interrogation of patient-derived AR mutation profiles for prognostic value. By correlating mutational landscapes with clinical outcomes, the researchers demonstrated that their functional atlas could serve as a robust biomarker platform to stratify patients based on the likelihood of therapeutic resistance and disease progression. This prognostic capability embodies the promise of precision medicine, where molecular insights translate directly into improved patient management.
This research represents a paragon of interdisciplinary collaboration, uniting molecular biology, genome editing technology, computational biology, and clinical oncology. The prime editing system employed is a testament to rapid advances in genome engineering tools, moving beyond conventional CRISPR-Cas9 nuclease systems towards safer and more precise modalities capable of modeling complex mutational spectra in human genes. The resulting high-resolution functional map of AR variants sets a new standard for variant interpretation in human genetics.
The authors meticulously validated several variants to confirm their functional annotations, employing biochemical assays, receptor binding studies, and gene expression profiling. These orthogonal validations reinforce the reliability of the screening data and underscore the robustness of the experimental framework. Such rigorous validation is essential when leveraging functional genomics data for clinical translation, ensuring that variant effect predictions are not merely statistical but biologically meaningful.
The study also navigates the intricate structural features of the AR ligand-binding domain, revealing how subtle amino acid substitutions perturb receptor conformation, ligand affinity, or co-factor interactions. Insights into these molecular mechanisms enrich understanding of AR signaling dynamics and open avenues for rational drug design, where structural considerations guide the creation of molecules tailored to circumvent specific resistance mutations.
Of note, the extensive dataset generated has been made accessible through publicly available databases, empowering the broader scientific community to mine this valuable resource for hypothesis generation and translational endeavors. Such openness fosters collaborative progress in tackling prostate cancer and androgen-related disorders, accelerating the pace at which discoveries are translated from bench to bedside.
Ultimately, this landmark study not only charts the vast mutational landscape of the androgen receptor but also establishes a paradigm for functional genomics investigations in complex, clinically important genes. Its innovative use of prime editing technology underscores the transformative potential of genome engineering in decoding human genetic variation with unprecedented resolution, providing a blueprint for future efforts aimed at personalized medicine.
This work heralds a new era in prostate cancer research and treatment, where comprehensive functional annotation of cancer driver mutations can inform tailored therapies, improve prognostic accuracy, and mitigate drug resistance. For patients facing the formidable challenges of prostate cancer or androgen insensitivity syndrome, the findings offer hope of more precise diagnoses and novel therapeutic strategies borne from a deep molecular understanding of AR biology.
Subject of Research:
Functional mapping of androgen receptor variants in prostate cancer and androgen insensitivity syndrome.
Article Title:
High-resolution functional mapping of androgen receptor variants.
Article References:
Oh, HC., Chang, Y., Park, J. et al. High-resolution functional mapping of androgen receptor variants. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01647-1
Image Credits:
AI Generated
DOI:
https://doi.org/10.1038/s41551-026-01647-1
Tags: androgen receptor ligand-binding domain mutationsandrogen receptor variants mappingAR antagonist resistance mechanismsAR variant atlas for precision medicineclinical diagnosis of androgen insensitivity syndromeCRISPR prime editing applicationsdeep mutational scanning of ARfunctional characterization of AR mutationsmolecular basis of androgen receptor signalingnovel therapies for prostate cancerprime editing in cancer researchprostate cancer drug resistance
